Quantbot Technologies LP Grows Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Quantbot Technologies LP increased its position in Exelixis, Inc. (NASDAQ:EXEL) by 93.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 11,092 shares of the biotechnology company’s stock after buying an additional 5,344 shares during the period. Quantbot Technologies LP’s holdings in Exelixis were worth $369,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Tri Ri Asset Management Corp bought a new position in shares of Exelixis in the third quarter worth about $4,396,000. Blue Trust Inc. boosted its stake in Exelixis by 134.7% in the 4th quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company’s stock worth $476,000 after purchasing an additional 8,208 shares during the period. Range Financial Group LLC purchased a new stake in Exelixis during the 4th quarter valued at approximately $994,000. FMR LLC raised its position in shares of Exelixis by 6.1% during the third quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company’s stock valued at $63,891,000 after buying an additional 140,568 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Exelixis by 82.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company’s stock worth $52,884,000 after buying an additional 704,786 shares in the last quarter. 85.27% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Exelixis news, EVP Patrick J. Haley sold 10,000 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $38.80, for a total value of $388,000.00. Following the transaction, the executive vice president now directly owns 341,028 shares in the company, valued at $13,231,886.40. This represents a 2.85 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $34.88, for a total transaction of $425,884.80. Following the sale, the director now directly owns 30,406 shares of the company’s stock, valued at $1,060,561.28. This represents a 28.65 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 140,343 shares of company stock valued at $5,177,234 in the last 90 days. Company insiders own 2.85% of the company’s stock.

Exelixis Stock Performance

EXEL opened at $36.70 on Friday. The stock’s 50 day moving average price is $35.71 and its 200-day moving average price is $33.22. Exelixis, Inc. has a one year low of $20.14 and a one year high of $40.02. The stock has a market cap of $10.27 billion, a price-to-earnings ratio of 20.73, a P/E/G ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. As a group, analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have issued reports on EXEL shares. Citigroup lifted their price target on shares of Exelixis from $38.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, February 12th. BMO Capital Markets downgraded Exelixis from an “outperform” rating to a “market perform” rating and boosted their target price for the stock from $36.00 to $40.00 in a research report on Friday, December 20th. UBS Group increased their price target on Exelixis from $30.00 to $34.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Exelixis in a research note on Thursday. Finally, Stephens reiterated an “equal weight” rating and set a $29.00 target price on shares of Exelixis in a research report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $37.59.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.